Focal Segmental Glomerulosclerosis (FSGS) Terminated Phase 1 Trials for Pamrevlumab (DB14952)

Also known as: Focal Glomerulosclerosis / Glomerulosclerosis, Focal / Focal Segmental Glomerulosclerosis / Glomerulosclerosis, Focal Segmental / APOL1-mediated focal segmental glomerulosclerosis / Focal & segmental glomerulosclerosis / Focal glomerular sclerosis (disorder) / Focal segmental glomerulosclerosis (disorder)

IndicationStatusPhase
DBCOND0038485 (Focal Segmental Glomerulosclerosis (FSGS))Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00782561Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)Treatment